Generic name:tildrakizumab-asmn
Dosage form: injection, solution
Drug class:Interleukin inhibitors
Medically reviewed by Drugs.com. Last updated on Apr 1, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Medication Guide
Indications and Usage for Ilumya Injection
ILUMYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Ilumya Injection Dosage and Administration
Dosage
ILUMYA is administered by subcutaneous injection. The recommended dose is 100 mg at Weeks 0, 4, and every twelve weeks thereafter. Each syringe contains 1 mL of 100 mg/mL tildrakizumab-asmn.
Tuberculosis Assessment Prior to Initiation of ILUMYA
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA [see
